If you’re wondering if Modafinil is safe to take after a TBI, read on to find out if this CNS stimulant really works. The good news is that it’s relatively safe compare to other CNS stimulants. Even better, it’s relatively effective for people with EDS and fatigue associated with TBI. So, what makes it so effective?
Modafinil ameliorates excessive daytime sleepiness.
The researchers at the University of Zurich, Switzerland, found that modafinil Modalert ameliorates excessive daytime sleepiness symptoms in individuals suffering from traumatic brain injury. The effects of modafinil are particularly evident after traumatic brain injury, where it is widely believe that the drug is a cause of excessive daytime sleepiness. In this study, modafinil was administer to patients with chronic traumatic encephalopathy and stroke.
The effects of modafinil on post-traumatic brain fatigue are not fully understood, however. The present study involved 27 patients with EDS. They were randomly assigne to receive either 400mg/day modafinil or a placebo for five days. Then, they underwent a driving test that required them to cross as few road-marked lines as possible. After five days, the two groups switched interventions, and the results were significant. The researchers also found a statistically significant relationship between the patients’ MWT scores and the number of inappropriate line crossings.
It is relatively safer than other CNS stimulants.
Although the exact mechanism of action of modafinil is not fully understood, it is thought to inhibit dopamine reuptake in the brain. Modalert 200 is use in the treatment of excessive daytime sleepiness related to conditions such as narcolepsy, shift work sleep disorder, and obstructive sleep apnea.
The treatment of excessive daytime sleepiness associated with traumatic brain injury is largely dependent on the type of underlying cause of the condition. In cases where no underlying cause can be find, wakefulness-promoting agents such as armodafinil and methylphenidate may be beneficial. However, the long-term safety of such agents is not fully known. Moreover, there are no clinical trials evaluating the safety and tolerability of modafinil in patients with traumatic brain injury conditions.
It is useful for patients with fatigue and/or EDS.
A recent study showed that a cognitive enhancer known as Modafinil is beneficial for patients with posttraumatic EDS and fatigue. In addition to improving alertness and cognitive functioning, Modafinil is also effective for people with posttraumatic headaches. Researchers also note that the drug is well tolerat in healthy adults. In the current study, a level-one trial was conduct with patients who were experiencing excessive daytime sleepiness after traumatic brain injury in an animal model.
Researchers in the United Kingdom enrolled 213 patients with a history of traumatic brain injury or stroke (TBI) and evaluated the effectiveness of (modafinil) Modvigil in reducing EDS and improving alertness. The study excluded individuals with a history of neuropsychiatric disease or sleep apnea. The results of the study are promising and should be interpret with caution.
It is relatively effective for patients with TBI.
The effectiveness of modafinil in treating posttraumatic fatigue and excessive daytime sleepiness (EDS) after traumatic brain injury is not yet establish. However, studies have shown that it can help alleviate posttraumatic EDS. Currently, a number of different therapies have been studied for this problem, including pharmacological treatments, behavioral therapy, and even acupuncture.
The study involved 20 patients who had either EDS or fatigue after TBI. Patients underwent baseline assessments including Epworth sleepiness scores, actigraphy, and polysomnography. After that, patients were randomly assign to receive modafinil or a placebo daily for six weeks. The researchers repeated these tests after each treatment. The researchers found that modafinil alleviated daytime sleepiness in patients treated with the drug.
In addition to proving the efficacy of modafinil in treating patients with TBI, the study showed that it improved CGI-S scores in a subset of TBI patients. The study did not specifically ask patients to disclose a history of TBI, so it may be difficult to determine whether it can help with excessive daytime sleepiness. In general, the study found that modafinil was able to reduce excessive daytime sleepiness after TBI, and that it significantly improved the patients’ quality of life.
